Donanemab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Donanemab" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

6web.archive.org

1^st place

6doi.org

2^nd place

3fda.gov

447^th place

338^th place

2semanticscholar.org

11^th place

8^th place

1theyucatantimes.com

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1alzforum.org

low place

1cnbc.com

220^th place

155^th place

1prnewswire.com

406^th place

258^th place

1alzheimersresearchuk.org

low place

1nytimes.com

7^th place

1handle.net

102^nd place

76^th place

alzforum.org

"Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit". AlzForum Foundation. 2021. Archived from the original on 23 April 2021. Retrieved 23 April 2021.

alzheimersresearchuk.org

"New Alzheimer's drug, donanemab – what is it and how does it work?". Alzheimer's Research UK. 23 October 2024. Retrieved 23 October 2024.

clinicaltrials.gov

"A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)". ClinicalTrials.gov. Retrieved 2 July 2024.

cnbc.com

"Eli Lilly Alzheimer's treatment donanemab slowed disease progression in clinical trial". CNBC. 3 May 2023. Archived from the original on 3 May 2023. Retrieved 3 May 2023.

doi.org

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. (May 2021). "Donanemab in Early Alzheimer's Disease". The New England Journal of Medicine. 384 (18): 1691–1704. doi:10.1056/NEJMoa2100708. PMID 33720637.
Long JM, Holtzman DM (October 2019). "Alzheimer Disease: An Update on Pathobiology and Treatment Strategies". Cell. 179 (2): 312–339. doi:10.1016/j.cell.2019.09.001. PMC 6778042. PMID 31564456.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. (August 2023). "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial". JAMA. 330 (6): 512–527. doi:10.1001/jama.2023.13239. PMC 10352931. PMID 37459141.
Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, et al. (December 2012). "A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice". Neuron. 76 (5): 908–20. doi:10.1016/j.neuron.2012.10.029. PMID 23217740. S2CID 16620402.
Gallardo G, Holtzman DM (2019). "Amyloid-β and Tau at the Crossroads of Alzheimer's Disease". Tau Biology. Advances in Experimental Medicine and Biology. Vol. 1184. pp. 187–203. doi:10.1007/978-981-32-9358-8_16. ISBN 978-981-32-9357-1. PMID 32096039. S2CID 211476346.
Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. (2021). "Donanemab (LY3002813) dose-escalation study in Alzheimer's disease". Alzheimer's & Dementia. 7 (1): e12112. doi:10.1002/trc2.12112. PMC 7882532. PMID 33614890.

fda.gov

"FDA approves treatment for adults with Alzheimer's disease". U.S. Food and Drug Administration (FDA) (Press release). 2 July 2024. Archived from the original on 2 July 2024. Retrieved 2 July 2024. This article incorporates text from this source, which is in the public domain.
"Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
"Notable Approvals". U.S. Food and Drug Administration (FDA). 2 July 2024. Archived from the original on 13 June 2024. Retrieved 3 July 2024.

handle.net

hdl.handle.net

World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.

nih.gov

pubmed.ncbi.nlm.nih.gov

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. (May 2021). "Donanemab in Early Alzheimer's Disease". The New England Journal of Medicine. 384 (18): 1691–1704. doi:10.1056/NEJMoa2100708. PMID 33720637.
Long JM, Holtzman DM (October 2019). "Alzheimer Disease: An Update on Pathobiology and Treatment Strategies". Cell. 179 (2): 312–339. doi:10.1016/j.cell.2019.09.001. PMC 6778042. PMID 31564456.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. (August 2023). "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial". JAMA. 330 (6): 512–527. doi:10.1001/jama.2023.13239. PMC 10352931. PMID 37459141.
Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, et al. (December 2012). "A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice". Neuron. 76 (5): 908–20. doi:10.1016/j.neuron.2012.10.029. PMID 23217740. S2CID 16620402.
Gallardo G, Holtzman DM (2019). "Amyloid-β and Tau at the Crossroads of Alzheimer's Disease". Tau Biology. Advances in Experimental Medicine and Biology. Vol. 1184. pp. 187–203. doi:10.1007/978-981-32-9358-8_16. ISBN 978-981-32-9357-1. PMID 32096039. S2CID 211476346.
Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. (2021). "Donanemab (LY3002813) dose-escalation study in Alzheimer's disease". Alzheimer's & Dementia. 7 (1): e12112. doi:10.1002/trc2.12112. PMC 7882532. PMID 33614890.

ncbi.nlm.nih.gov

Long JM, Holtzman DM (October 2019). "Alzheimer Disease: An Update on Pathobiology and Treatment Strategies". Cell. 179 (2): 312–339. doi:10.1016/j.cell.2019.09.001. PMC 6778042. PMID 31564456.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. (August 2023). "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial". JAMA. 330 (6): 512–527. doi:10.1001/jama.2023.13239. PMC 10352931. PMID 37459141.
Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. (2021). "Donanemab (LY3002813) dose-escalation study in Alzheimer's disease". Alzheimer's & Dementia. 7 (1): e12112. doi:10.1002/trc2.12112. PMC 7882532. PMID 33614890.

dailymed.nlm.nih.gov

"Kisunla- donanemab-azbt injection, solution". DailyMed. 2 July 2024. Retrieved 15 August 2024.

nytimes.com

Belluck P (2 July 2024). "New Drug Approved for Early Alzheimer's". The New York Times. Archived from the original on 2 July 2024. Retrieved 3 July 2024.

prnewswire.com

"Lilly's Kisunla (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease" (Press release). Eli Lilly. 2 July 2024. Archived from the original on 2 July 2024. Retrieved 2 July 2024 – via PR Newswire.

semanticscholar.org

api.semanticscholar.org

Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, et al. (December 2012). "A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice". Neuron. 76 (5): 908–20. doi:10.1016/j.neuron.2012.10.029. PMID 23217740. S2CID 16620402.
Gallardo G, Holtzman DM (2019). "Amyloid-β and Tau at the Crossroads of Alzheimer's Disease". Tau Biology. Advances in Experimental Medicine and Biology. Vol. 1184. pp. 187–203. doi:10.1007/978-981-32-9358-8_16. ISBN 978-981-32-9357-1. PMID 32096039. S2CID 211476346.

theyucatantimes.com

"FDA approves treatment for Alzheimer's disease - The Yucatan Times". 12 July 2024. Retrieved 15 July 2024.

web.archive.org

"FDA approves treatment for adults with Alzheimer's disease". U.S. Food and Drug Administration (FDA) (Press release). 2 July 2024. Archived from the original on 2 July 2024. Retrieved 2 July 2024. This article incorporates text from this source, which is in the public domain.
"Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit". AlzForum Foundation. 2021. Archived from the original on 23 April 2021. Retrieved 23 April 2021.
"Eli Lilly Alzheimer's treatment donanemab slowed disease progression in clinical trial". CNBC. 3 May 2023. Archived from the original on 3 May 2023. Retrieved 3 May 2023.
"Notable Approvals". U.S. Food and Drug Administration (FDA). 2 July 2024. Archived from the original on 13 June 2024. Retrieved 3 July 2024.
"Lilly's Kisunla (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease" (Press release). Eli Lilly. 2 July 2024. Archived from the original on 2 July 2024. Retrieved 2 July 2024 – via PR Newswire.
Belluck P (2 July 2024). "New Drug Approved for Early Alzheimer's". The New York Times. Archived from the original on 2 July 2024. Retrieved 3 July 2024.